Preoperative interleukin-6 production by mononuclear blood cells predicts survival after radical surgery for colorectal carcinoma

Cancer

Volumn 109, Issue 9, 2007, Pages 1742-1749

  Clinchy, Birgitta ^a   Fransson, Annelie ^a   Druvefors, Bengt ^a   Hellsten, Anna ^a   Håkansson, Annika ^a   Gustafsson, Bertil ^a   Sjödahl, Rune ^a   Håkansson, Leif ^a  

^a LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Colorectal carcinoma; Interleukin 6; Prediction; Preoperative; Radical resection; Survival

Indexed keywords

CAPECITABINE; FLUOROURACIL; FOLINIC ACID; INTERLEUKIN 6;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; COLORECTAL CARCINOMA; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; MALE; MONONUCLEAR CELL; PREDICTION; PREOPERATIVE RADIOTHERAPY; PRIORITY JOURNAL; PROGNOSIS;

AGED; AGED, 80 AND OVER; COLORECTAL NEOPLASMS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INTERLEUKIN-6; KAPLAN-MEIERS ESTIMATE; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 34247615901     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.22623     Document Type: Article

References (36)

1. Graziano F, Catalano V, Baldelli AM, Cascinu S. Prognostic biomarkers in resected colorectal cancer: implications for adjuvant chemotherapy. Expert Rev Anticancer Ther. 2001;1:247-257.
2. Pasche B, Mulcahy M, Benson AB 3rd. Molecular markers in prognosis of colorectal cancer and prediction of response to treatment. Best Pract Res Clin Gastroenterol. 2002;16:331-345.
3. Klump B, Nehls O, Okech T, et al. Molecular lesions in colorectal cancer: impact on prognosis? Int J Colorectal Dis. 2004;19:23-42.
4. Bustin SA, Dorudi S. Gene expression profiling for molecular staging and prognosis prediction in colorectal cancer. Expert Rev Mol Diagn. 2004;4:599-607.
5. Nakagoe T, Sawai T, Ayabe H, et al. Prognostic value of carcinoembryonic antigen (CEA) in tumor tissue of patients with colorectal cancer. Anticancer Res. 2001;21:3031-3036.
6. Jass JR. Lymphocytic infiltration and survival in rectal cancer. J Clin Pathol. 1986;39:585-589.
7. Naito Y, Saito K, Shiiba K, et al. CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res. 1998;58:3491-3494.
8. Nozoe T, Matsumata T, Kitamure M, Sugimachi K. Significance of preoperative elevation of serum C-reactive protein as an indicator for prognosis in colorectal cancer. Am J Surg. 1998;176:335-338.
9. Chung C-H, Chang Y-F. Serum C-reactive protein correlates with survival in colorectal cancer patients but is not an independent prognostic indicator. Eur J Gastroenterol Hepatol. 2003;15:369-373.
10. Canna K, McMillan DC, McKee RF, et al. Evaluation of a cumulative prognostic score based on the systemic inflammatory response in patients undergoing potentially curative surgery for colorectal cancer. Br J Cancer. 2004;90:1707-1709.
11. Lotz M. Interleukin-6: a comprehensive review. Cancer Treat Res. 1995;80:209-233.
12. Lauta VM. Interleukin-6 and the network of several cytokines in multiple myeloma: an overview of clinical and experimental data. Cytokine. 2001;16:79-86.
13. Fayad L, Keating MJ, Reuben JM, et al. Interleukin-6 and interleukin-10 levels in chronic lymphocytic leukemia: correlation with phenotype characteristics and outcome. Blood. 2001;97:256-263.
14. Ljungberg B, Grankvist K, Rasmuson T. Serum interleukin-6 in relation to acute-phase reactants and survival in patients with renal cell carcinoma. Eur J Cancer. 1997;33:1794-1798.
15. Nakashima J, Tachibana M, Horiguchi Y, et al. Serum interleukin 6 as a prognostic factor in patients with prostate cancer. Clin Cancer Res. 2000;6:2702-2706.
16. Scambia G, Testa U, Panici B, et al. Prognostic significance of interleukin 6 serum levels in patients with ovarian cancer. Br J Cancer. 1995;71:354-356.
17. Zhang GJ, Adachi I. Serum interleukin-6 levels correlate to tumor progression and prognosis in metastatic breast carcinoma. Anticancer Res. 1999;19:1427-1432.
18. Salgado R, Junius S, Benoy I, et al. Circulating interleukin-6 predicts survival in patients with metastatic breast cancer. Int J Cancer. 2003;103:642-646.
19. Ebrahimi B, Tucker SL, Donghui L, et al. Cytokines in pancreatic carcinoma. Correlation with phenotypic characteristics and prognosis. Cancer. 2004;101:2727-2736.
20. Berghella AM, Pellegrini P, Del Beato T, et al. Prognostic significance of immunological evaluation of colorectal cancer. Cancer Biother Radiopharm. 1996;11:355-361.
21. Pellegrini P, Berghella M, Del Beato T, et al. Disregulation in TH1 and TH2 subsets of CD4+ T cells in peripheral blood colorectal cancer patients and involvement in cancer establishment and progression. Cancer Immunol Immunother. 1996;42:1-8.
22. Kinoshita T, Hideki I, Miki C. Serum interleukin-6 level reflects the tumor proliferative activity in patients with colorectal carcinoma. Cancer. 1999;85:2526-2531.
23. Belluco C, Nitti D, Frantz M, et al. Interleukin-6 blood level is associated with circulating carcinoembryonic antigen and prognosis in patients with colorectal cancer. Ann Surg Oncol. 2000;7:133-138.
24. De Vita F, Romano C, Orditura M, et al. Interleukin-6 serum levels correlates with survival in advanced gastrointestinal cancer patients but is not an independent prognostic indicator. J Interferon Cytokine Res. 2001;21:45-52.
25. Galizia G, Lieto E, De Vita F, et al. Circulating levels of interleukin-10 and interleukin-6 in gastric and colon cancer patients before and after surgery: relationship with radicality and outcome. J Interfon Cytokine Res. 2002;22:473-482.
26. Odermann J, Jacobi CA, Braumann C, et al. Immunomodulatory changes in patients with colorectal cancer. Int J Colorectal Dis. 2002;17:37-41.
27. Chung C-H, Chang Y-F. Serum interleukin-6 levels reflect the disease status of colorectal cancer. J Surg Oncol. 2003;83:222-226.
28. Alkira S, Kishimoto T. The evidence for interleukin-6 as an autocrine growth factor in malignancy. Semin Cancer Biol. 1992;3:17-26.
29. Tafuto S, Silvestri I, Dandrea P, et al. Interleukin-6: biological features and clinical implications. J Biol Regul Homeost Agents. 1994;8:1-8.
30. Miki C, Tonouchi H, Wakuda R, et al. Intra-tumoral interleukin-6 down-regulation and genetic mutations of tumor suppressor genes in colorectal carcinoma. Cancer. 2002;94:1584-1592.
31. Nara K, Odagiri H, Fujii M, et al. Increased production of tumor necrosis factor and prostaglandin E2 by monocytes in cancer patients and its unique modulation by their plasma. Cancer Immunol Immunother. 1987;25:126-132.
32. Shibata M, Nezu T, Kanou H, et al. Decreased production of interleukin-12 and type 2 immune responses are marked in cachectic patients with colorectal and gastric cancer. J Clin Gastroenterol. 2002;34:416-420.
33. Arbour NC, Lorenz E, Schutte BC, et al. TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nat Genet. 2000;25:187-191.
34. Parry SL, Sebbag M, Feldmann M, et al. Contact with T cells modulates monocyte IL-10 production: role of T cell membrane TNF-alpha. J Immunol. 1997;158:3673-3681.
35. Piancatelli D, Romano P, Sebastiani P, et al. Local expression of cytokines in human colorectal carcinoma: evidence of specific interleukin-6 gene expression. J Immunother. 1999;22:25-32.
36. North R. Down-regulation of the antitumor immune response. Adv Cancer Res. 1985;45:1-43.